Cancer Management Guidelines
-
Multiple Myeloma (MM)
Publications
Updated: April 2011
2011
-
Venner C, Connors J, Sutherland H, Shepherd J, Hamata L, Abou Mourad Y, Barnett M, Broady R, Forrest D, Hogge D, Nantel S, Narayanan S, Nevill T, Nitta J, Power M, Toze C, Smith C, and Song, K.
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leukemia & Lymphoma, January 2011; 52(1): 34–41.
Venner Leuk Lymph 2011
2009
- Reece D, Song KW, Fu T, Roland B, Chang H, Horsman D, Mansoor A, Chen C, Masih-Khan E, Trieu Y, Bruyere H, Stewart DA and Bahlis NJ. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522-525.
Reece_2009_Blood
2007
- Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoid JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Long Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation. 2007;13:925-931.
Kuruvilla_2007_Biol Blood Marrow Transplant - Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Survorov AN, Zhuang SH, Perekh T, Ziu L, Yuan Z, Rackoff W and Harousseau J-L. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared with Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. J Clin Oncol. 2007;25:3892-3901.
Orlowski_2007_J Clin Oncol
| The information contained in these guidelines is a statement of consensus of Leukemia/BMT Program of BC professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these guidelines and documents is at your own risk and is subject to the Leukemia/BMT Program of BC’s terms of use available at Terms of Use. |